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Abstract
Background: Biochemical recurrence (BCR) is widely used to define the treatment success and to make decisions
on if or how to initiate a secondary therapy, but uniform criteria to define BCR after radical prostatectomy (RP) is
not yet completely assessed. UHRF1 has a unique function in regulating the epigenome by linking DNA methylation
with histone marks. The clinical value of UHRF1 in PCa has not been well done. Therefore, we evaluated the prognostic
significance of UHRF1.
Method: UHRF1 expression in PCa cells was monitored by qRT-PCR and Western blot analyses. UHRF1 expression was
knocked down using specific siRNAs, and the effects of knockdown on the proliferation, migration, cell cycle,
and apoptosis of PCa cell lines were investigated. UHRF1 protein expression was evaluated in 225 PCa specimens using
immunohistochemistry in tissue microarrays. Correlations between UHRF1 expression and the clinical features of PCa
were assessed.
Results: The results showed that UHRF1 was overexpressed in almost all of the PCa cell lines. In PCa cells,
UHRF1 knockdown inhibited cell proliferation and migration, and induced apoptosis. UHRF1 expression levels
were correlated with some clinical features of PCa. Multivariate analysis showed that UHRF1 expression was
an independent prognostic factor for biochemical recurrence-free survival.
Conclusions: UHRF1 functions as an oncogene in prostate cancer and appears to be capable of predicting
the risk of biochemical recurrence in PCa patients after radical prostatectomy, and may serve as a potential
therapeutic target for PCa.
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Background
Prostate cancer (PCa) is the most common genitourinary
malignancy in males worldwide. Since the advent of
prostate-specific antigen (PSA) testing in the late 1980s,
different diagnostic and treatment approaches for PCa
have been developed [1]. Currently, radical prostatec-
tomy (RP) is the primary treatment for localized PCa [2].
However, during long-term follow-up after RP, about
25–50 % of patients develop biochemical recurrence
(BCR), which is generally the earliest indicator of recur-
rent disease [3]. BCR is widely used to define the treat-
ment success and to make decisions on if or how to
initiate a secondary therapy, but uniform criteria to de-
fine BCR after radical prostatectomy (RP) is not yet
completely assessed. EAU guidelines define a PSA cutoff
post-RP of ≥0.2 ng/ml [4]. Although at least 10 defini-
tions of BCR have been proposed. PSA levels ≥4 ng/ml
have been shown to have the highest correlation with
the risk of clinical progression, which tightly associates
with metastatic disease progression (MP) and prostate
cancer–specific mortality (PCSM) [5]. Furthermore, PSA
kinetics is relevant for the BRC definition. EAU guide-
lines define BCR when two sequential PSA values post-
* Correspondence: quicktao@sina.com; yaoli@fudan.edu.cn
1Department of Urology, Tongji Hospital, Tongji University School of
Medicine, Shanghai 200065, People’s Republic of China
2State Key Laboratory of Genetic Engineering, Institute of Genetics, School of
Life Science, Fudan University, Shanghai 200433, People’s Republic of China
Full list of author information is available at the end of the article
© 2016 Wan et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wan et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:34 
DOI 10.1186/s13046-016-0308-0
RP are ≥0.2 ng/ml. CAU (China Urological Association)
guidelines define BCR in agreement with that of EAU so
BCR in this study is defined as two sequential PSA
values post-RP ≥ 0.2 ng/ml. Patients with an equivalent
PSA level, Gleason score, and pathological stage can
have different clinical outcomes for PCa, depending on
which molecular heterogeneous subtypes is involved [6].
Therefore, developing a better understanding of the
molecular pathology of PCa is critical for establishing
effective indicators of prognosis and therapeutic strat-
egies against this potentially fatal disease.
Ubiquitin-like, containing PHD ring finger 1 (UHRF1,
also known as ICBP90) was originally identified as a pro-
tein whose subcellular expression pattern coincided with
sites of DNA replication [7, 8]. UHRF1 is characterized
by a SET and ring-associated (SRA) domain, which is
found only in the UHRF family. UHRF1 transmits the
DNA methylation status from mother to daughter cells
by recognizing hemimethylated DNA, recruiting DNA
methyltransferase 1, and proliferating cell nuclear anti-
gen to the site to methylate newly synthesized DNA
strands [9–12]. UHRF1 also binds histone H3 that is tri-
methylated at lysine 4 and 9 (H3K4me3 and H3K9me3),
and UHRF1 plays a role in maintaining this histone
modification in heterochromatin [13, 14]. Thus, UHRF1
has a unique function in regulating the epigenome by
linking DNA methylation with histone marks [15, 16].
Previously, we showed that the H3 trimethylation sta-
tus at lysine 4 can predict the risk of BCR in low-grade
PCa (Gleason score ≤ 6) after RP [17]. Therefore, UHRF1
might play an important role in tumourigenesis in the
prostate. Expression of UHRF1 is upregulated in several
cancers (e.g., breast, lung, pancreatic, and cervical can-
cers) [18–21], suggesting that this protein is involved
cancer development and progression. If so, then UHRF1
could be an important diagnostic biomarker and prog-
nostic indicator for cancer. However, the expression and
functional roles of UHRF1 in PCa remain unclear.
In this study, the expression of UHRF1 in PCa was
analysed at the cell and tissue levels. The aims of this
study were to investigate whether UHRF1 could be a
novel diagnostic marker and used as a therapeutic target
in PCa, to determine the underlying molecular mechan-




Tumour or tissue samples were extracted from patients
with PCa (n = 225), prostatic intraepithelial neoplasia
(PIN; n = 19), or normal prostates (n = 25). Normal pros-
tate tissue was obtained from patients with bladder can-
cer after total cystectomy. PCa and PIN tissues were
from patients with PCa who underwent RP and regional
lymph node (LN) dissection at TongJi Hospital, a
subsidiary of TongJi University, between January 2001
and December 2013. Patients did not receive any pre-
operative treatment. Histopathologic features of the
tumour samples were classified according to the Gleason
scoring system and the 2002 TNM classification system.
The Research Ethics Committee of TongJi Hospital ap-
proved this protocol, and verbal consent was obtained
from all patients.
Prostate tissue microarray and immunohistochemical
analyses
A prostate tissue microarray (TMA) was constructed
using formalin-fixed, paraffin-embedded prostate tissue
samples. Areas of invasive adenocarcinoma were identi-
fied according to the corresponding haematoxylin and
eosin (H&E)-stained slides. Two replicate tumour sam-
ples (1 mm in diameter) were taken from the donor tis-
sue blocks in a highly representative fashion and arrayed
into a recipient paraffin block (35 mm× 622 mm ×
65 mm) using a tissue microarrayer (Beecher Instrument
Inc., Sun Prairie, WI), as previously described [22].
UHRF1 was detected with a specific rabbit polyclonal
antibody (ab52039, Abcam Inc., Cambridge, MA), which
was tested and optimized on whole-tissue sections and
test arrays. Once an appropriate dilution (1:100) and in-
cubation time had been determined, two TMA sections
containing all of the patient samples were stained for
UHRF1 by standard two-step immunohistochemistry.
Immediately before staining, the TMA sections were cut
with a sectioning aid (Instrumedics, St. Louis, MO),
deparaffinised in xylene, and rehydrated in a graded
alcohol series. Endogenous peroxidase was quenched
with 0.3 % hydrogen peroxide in methanol at room
temperature (24 °C). Sections were placed in a 120 °C,
0.01 M sodium citrate buffer (pH 6.0) for antigen retrieval.
The Dako Envision System was used as the secondary
antibody. Sections were visualized with diaminobenzidine
(DAB), counterstained with haematoxylin, dehydrated,
and mounted. Identical TMA sections stained without pri-
mary antibody served as negative controls.
Two blinded observers performed independent semi-
quantitative assessments of antibody staining on the
TMA sections. Each TMAs spot was scanned to assign
the scores. UHRF1 expression was estimated as the total
UHRF1 immunostaining score, which was calculated as
the sum of an extent of staining score and an intensity
score. The extent of staining score reflects the fraction
of positive staining cells (score 0, 0 %; score 1, 1–25 %;
score 2, 26–50 %; score 3, 51–75 %; score 4, 76–100 %).
The intensity score represents the staining intensity
(score 0, no staining signal; score 1, weak positive signal;
score 2, moderate positive signal; score 3, strong positive
signal). The sum of the intensity and extent of staining
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scores were used as the final staining score (0–7) for
UHRF1. This relatively simple, reproducible scoring
method gives highly concordant results between inde-
pendent evaluators and has been used in previous
studies [23]. For the purpose of statistical evaluation,
tumours with a final staining score of ≥ 3 were con-
sidered to be UHRF1-positive.
Image acquisition and management
Digital images were captured using the Nikon DS-Ri1
ECLIPSE Series (Nikon, Tokyo, Japan) with a 10× object-
ive. TMA images were managed using NIS Element D4.00
software (Nikon).
Cell culture
The PCa cell line LNCaP was purchased from the
American Type Culture Collection (Manassas, VA) and
confirmed by short tandem repeat (STR) analysis. PCa
cell lines 22RV1, DU145, and PC-3 were obtained from
the Cell Bank of the Chinese Academy of Sciences
(Shanghai, China) and were authenticated by myco-
plasma detection, DNA fingerprinting, isozyme detec-
tion, and cell vitality detection. All experiments were
carried out with each cell line prior to passage 30. Cell
lines were grown in RPMI 1640 medium supplemented
with 10 % FBS, 1 % penicillin/streptomycin, 1 % nones-
sential amino acids, and 1 % mg/mL sodium pyruvate,
and cultured at 37 °C in 5 % CO2. All cell culture re-
agents were purchased from Life Technologies (Grand
Island, NY).
RNA interference
Cells were seeded in 12-well plates and transfected with
siRNAs using Lipofectamine 2000 (Life Technologies), in
accordance with the manufacturer’s instructions. All
siRNA oligonucleotides were synthesized by GenePharma
(Shanghai, China). The following siRNAs were used:
siUHRF1-535: 5′-GCCAGAGUGA GUCAGACAAT T-3′
and 5′-UUGUCUGACU CACUCUGGCT T-3′; siUHR
F1-1453: 5′-GCACCAAGGA AUGUACCAUT T-3′ and
5′-AUGGUACAUU CCUUGGUGCT T-3′; and a scram-
bled siRNA control: 5′-UUCUCCGAAC GUGUCACGUT
T-3′ and 5′-ACGUGACACG UUCGGAGAAT T-3′.
Plasmids and cell transfection
Human cDNA of UHRF1 was was provided by Dr.
Jiahuai Han (Xiamen University). Full-length cDNA of
UHRF1 was cloned into expression plasmid pcDNA3.1(+)
(Invitrogen). Transfections were carried out using Lipofec-
tamine 2000, in accordance with the manufacturer’s
protocol. The day before transfection, cells were seeded in
six-well plates. A 800-ng sample of pcDNA3.1(+) or
pcDNA3.1(+)-UHRF1 plasmid in 250 μL Opti-MEM
medium (Life Technologies) was mixed with 5 μL of
Lipofectamine 2000 dissolved in 250 μL of the same
medium and allowed to stand at room temperature for
20 min. The resulting transfection solution (500 μL) was
added to each well, which already contained 1.5 mL of
Opti-MEM. Four hours later, the media was replaced with
2 mL of fresh RPMI 1640 medium.
Real-time reverse transcription PCR analysis
Total RNA was extracted from 22RV1, DU145, PC-3,
and LNCaP cells with Trizol reagent (Invitrogen). Re-
verse transcription was performed with the PrimeScript
RT reagent kit (TaKaRa, Tokyo, Japan), by following the
manufacturer’s protocol. Real-time quantitative PCR
(qPCR) was performed using an ABI Prism 7900HT
(Applied Biosystems, Foster City, CA). Primers for
UHRF1 were: forward, 5′-TTGGCCAGAG TGCAAA
TGGA AGATCCAGGA GCTGTTCCA-3′ and reverse,
5′-AAGAGGGTAT GGCCGTCCTT CGGCTGTTTC
TTGATTTTTG TAA-3′. Primers for β-actin were: for-
ward, 5′-CCTCTCCCAA GTCCACACAG TGACG
CTGGG GCTGGCATTG-3′ and reverse, 5′-GGGCAC-
GAAG GCTCATCATT GCTCTTGCTG GGGCTG
GTGG-3′. Primers were synthesized by SangonSBS
Gentech Biotech (Shanghai, China). To determine the
UHRF1 expression levels, Ct values were normalized
to β-actin as an internal control. The relative mRNA
expression was calculated using the 2-ΔΔCt method.
Each sample was run in triplicate to ensure accuracy.
Western blot analysis
Cells were harvested 48 h after siRNA transfection by
using a 1× SDS lysis buffer (50 mM Tris-HCl [pH 6.8],
100 mM DTT, 2 % SDS, 0.1 % bromphenol blue, 10 %
glycerol). The protein concentration was determined by the
BCA Protein Assay (Thermo Fisher Scientific, Waltham,
MA), in accordance with the manufacturer's instructions.
Proteins were separated by SDS-PAGE on a 12 % (w/v)
polyacrylamide gel and transferred to membranes.
Standard Western blot analyses were performed to
measure the expression of β-actin (Sigma-Aldrich,
MO). Secondary antibodies were purchased from
Sigma-Aldrich. Signal intensities of the Western blots
were quantified with the Quantity One software pack-
age (Bio-Rad, CA).
Cell proliferation assay
Cell proliferation analysis was performed with Cell Count-
ing Kit-8 (CCK-8; Dojindo Laboratories, Kumamoto,
Japan), in accordance with the manufacturer’s protocol.
Briefly, 5000 cells were seeded into each well of a 96-well
plate. Proliferation was assessed at 0, 24, 48, 72, 96, and
120 h. CCK-8 (10 μL) was added to the well being har-
vested at each time point. Cells were incubated with CCK-
8 for 2 h at 37 °C, and the absorbance at 450 nm was
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measured with a Microplate Reader ELx808 (Bio-Tek In-
struments, Winooski, VT). The absorbance at 630 nm was
used as a reference. Each experiment was performed at
least in triplicate.
Cell cycle assay
At 48 h after transfection, cells were removed from the
culture plates with trypsin and washed with PBS. Cells
were incubated with PBS containing 0.03 % Triton X-
100, 100 ng/mL RNase A, and 50 ng/mL propidium
iodide (PI) for 15 min in the dark. The percentage of
cells in different cell cycle phases was measured with
a FACStar flow cytometer (Becton-Dickinson, San Jose,
CA) and analysed with ModFit software (Verity Software
House, Topsham, ME).
Annexin V-FITC apoptosis detection
Cells were seeded into 6-well plates and cultured for
48 h. Cells were collected 48 h after transfection. The
level of apoptosis was determined with the FITC
Annexin V Apoptosis Detection Kit (Becton-Dickinson)
on a FACSCalibur flow cytometer (Becton-Dickinson),
in accordance with the manufacturer’s instructions.
Cell migration assay
Cell migration assays were performed in Transwell
plates (8-μm pore size, 6.5-mm diameter; Corning Life
Sciences, Lowell, MA), in accordance with the manufac-
turer’s protocol. Briefly, 2 × 104 cells in 0.1 mL medium
(supplemented with 1 % FBS) were seeded into the
upper chamber of a Transwell plate, with 0.7 mL of
medium (supplemented with 10 % FBS) in the lower
chamber. Plates were incubated in a humidified incuba-
tor at 37 °C and 5 % CO2. After 120 h, the chambers
were removed, and a cotton swab was used to scrape the
cells that had not migrated from the upper side of the
chamber. Cells in the lower chamber were fixed with
methanol for 10 min, stained with 5 % Giemsa solution
for 5 min, and washed twice with PBS. Cells that
migrated through the Matrigel were counted using a
microscope. For this assay, cells were treated with one of
three siRNAs: scrambled siRNA (negative control),
siUHRF1-535, or siUHRF1-1453. Cell migration was de-
tected in triplicate for each siRNA, and the experiment
was repeated three times.
Statistical analysis
Numerical data are expressed as the mean ± standard de-
viation (SD). All in vitro experiments were performed at
least three times. BCR is defined as two sequential PSA
values post-RP ≥ 0.2 ng/ml. The BCR-free survival time
was regulated as the time from the date of surgery to
BCR. Follow-up data were updated in December 2013.
The probability of survival was estimated using the
Kaplan-Meier method. The log-rank test was used to
compare differences in survival times. To analyse the re-
lationship between UHRF1 expression and the clinical
characteristics of the tumours, the chi-squared test, t-
test, Fisher’s Exact test, or Mann-Whitney U-test was
used as appropriate. A Cox proportional hazards model
was used to establish independent factor(s) that pre-
dicted survival. All tests were two-sided, and statistical
significance was set at p < 0.05. Statistical analysis was
performed using the SPSS software package, version 15.0
(SPSS Inc., Chicago, IL).
Results
Expression levels of UHRF1 mRNA and protein in PCa
cell lines
The mRNA and protein expression levels of UHRF1 were
evaluated in the human PCa cell lines 22RV1, DU145, PC-
3, and LNCaP by qRT-PCR and Western blot analyses,
respectively (Fig. 1a-c). LNCaP is androgen-dependent
prostate cancer (ADPCa) cell line, 22Rv1 is weakly
androgen-dependent cell line, PC-3 and DU145 are
androgen-independent prostate cancer (AIPCa) cell lines.
Compared with the less aggressive LNCaP cells, androgen-
independent prostate cancer (AIPCa) cell lines DU145 and
PC-3 over-expressed UHRF1 in both mRNA and protein
levels. Our results were consistent with Babbio’s findings
[24]. The finding raised the possibility that the differentially
expressed UHRF1 might contribute to the progression of
prostate cancer.
To characterize the function of UHRF1 in PCa,
UHRF1 siRNA was used to knockdown UHRF1 expres-
sion at the mRNA and protein levels. Compared to
treatment with the scrambled siRNA control, UHRF1-
specific siRNA substantially decreased UHRF1 mRNA
and protein levels in LNCaP and PC-3 cells (Fig. 1d-i).
Subsequently, we transfected LNCaP and PC-3 cells with
the expression plasmid pcDNA 3.1(+) containing the
UHRF1 gene. We observed a significant increase of
UHRF1 gene expression at both mRNA and protein
levels in the transfected cells (Fig. 1j-l).
UHRF1 influences cell proliferation and cell cycle status in
PCa cell lines
We characterized the role of UHRF1 in other cellular
processes in PCa cell lines. First, we evaluated the effect
of UHRF1 on cell proliferation in LNCaP and PC-3 cells.
When cell lines were transfected with siRNA against
UHRF1 (siUHRF1), proliferation was decreased com-
pared to cells treated with the nonspecific scrambled
siRNA (p < 0.001, Fig. 2a, b, d and e). In addition, we
further examined the effect of ectopic UHRF1 expres-
sion on cell proliferation in LNCaP and PC-3 cells. As
shown in Fig. 2, overexpression of UHRF1 significantly
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promoted proliferation of LNCaP and PC-3 cells com-
pared to negative control cells (Fig. 2c and f).
Given that the cell cycle distribution reflects cell growth,
we assessed the influence of UHRF1 on the cell cycle pro-
file of LNCaP and PC-3 cells by flow cytometry. Knock-
down of UHRF1 in LNCaP and PC-3 cells increased the
percentage of cells in G1 phase and decreased the percent-
age of cells in S phase compared to treatment with the
nonspecific scrambled siRNA (p < 0.001; Fig. 3a and b).
Furthermore, UHRF1 overexpression slightly induced the
decrease in G1 phase and the increase in S phase of
LNCaP (p < 0.05; Fig. 3c). Taken together, these results
Fig. 1 Expression levels of UHRF1 mRNA and protein in PCa cell lines. a Expression of UHRF1 mRNA in LNCaP, 22RV1, DU145, and PC-3 cells. b, c
Western blot examination of UHRF1 protein levels in LNCaP, 22RV1, DU145, and PC-3 cells. d, g Expression of UHRF1 mRNA after transfection with
the indicated siRNAs in LNCaP and PC-3cells. e, f Western blot analysis of UHRF1 protein levels in LNCaP cells 24 h after transfection. h, i Western
blot analysis of UHRF1 protein levels in PC-3 cells 24 h after transfection. j Expression of UHRF1 mRNA after transfection with expression plasmid
pcDNA 3.1(+)-UHRF1 in LNCaP and PC-3cells. k, l Western blot analysis of UHRF1 protein levels in PC-3 cells 24 h after transfection. Parts c, f, i and
l show the relative grey values of each band (normalized to β-actin). Protein bands from three independent Western blot assays were quantified
using Quantity One software (Bio-Rad, USA). Data are reported as the mean ± SD (** p < 0.01, Student’s t-test)
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Fig. 2 UHRF1 promoted cell proliferation in PCa cells. Cells were seeded into a 96-well plate at 5000 cells/well and examined at 0, 24, 48, and
72 h after transfection. Each experiment was performed in triplicate (n = 3). Knockdown of UHRF1 inhibited cell proliferation in LNCaP (a, b) and
PC-3 (c, d) cells. Overexpression of UHRF1 promoted cell proliferation in LNCaP (c) and PC-3 (f) cells
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indicate that UHRF1 increased the proliferation and
growth of LNCaP and PC-3 cells by promoting cell cycle
progression.
UHRF1 suppresses apoptosis of prostate cancer cells
We next explored the role of UHRF1 in apoptosis in
PCa. LNCaP, PC-3 and 22Rv1 cells were treated with
siUHRF1 or a scrambled nonspecific siRNA control,
stained with Annexin V-FITC/PI, and analysed by flow
cytometry. Knockdown of UHRF1 in LNCaP, PC-3 and
22Rv1 cells increased the early and late apoptotic cell
fractions (p < 0.05; Fig. 4a-c). As expected, we found that
overexpression of UHRF1 in LNCaP cells decreased the
fraction of apoptotic cells (p < 0.01; Fig. 4d).
Effects of UHRF1 siRNA on the migration of PCa cells
in vitro
The migratory ability of PC-3 cells was estimated from
the number of cells that migrated through the filter of a
Transwell chamber (Fig. 5). The numbers of migrating
cells were decreased by 4.737- and 1.91-fold in
siUHRF1-535– and siUHRF1-1453–treated PC-3 cells,
respectively, compared with the scrambled siRNA-
treated control group (p < 0.001).
Fig. 3 UHRF1 influenced cell cycle status in PCa cells. Cells were transfected with siUHRF1-535, siUHRF1-1453, siNC, pcDNA3.1(+) or pcDNA3.1(+)-
UHRF1 plasmid for 48 h, stained with propidium iodide (PI), and used for cell cycle analysis. Treatment with siUHRF1 decreased the percentage of
cells in G1 phase and increased the percentage in S phase in LNCaP (a) and PC-3 (b) cells. Overexpression of UHRF1 induced the decrease in G1
phase and the increase in S phase of LNCaP cells (c). Each experiment was performed in triplicate
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UHRF1 expression in PCa tissue samples and associations
with PCa clinical variables
Of the 225 patients with PCa who were included in
the study, tissue samples from 106 patients (47.1 %)
were positive for UHRF1 protein expression by
immunostaining. As shown in Fig. 6, UHRF1 ex-
pression was higher in PCa samples compared to
PIN samples (2/19; 10.5 %) or normal prostate tis-
sue samples (1/24; 4.0 %; χ2 = 24.982, p < 0.000;
Fig. 6d-f ).
Fig. 4 UHRF1 inhibited prostate cancer cell apoptosis. Cells were transfected with siUHRF1-535, siUHRF1-1453, siNC, pcDNA3.1(+) or pcDNA3.1(+)-
UHRF1 plasmid for 48 h, and then subjected to cell apoptosis (stained with PI and FITC-Annexin V). Knockdown of UHRF1 caused an increase in
early and late apoptotic cells and a decrease in living cells in LNCaP (a, b), 22RV1 (c, d) and PC-3 (e, f). Overexpression of UHRF1 decreased the
fraction of apoptotic cells in LNCaP cells (g, h). Each experiment was performed in triplicate
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Associations between UHRF1 protein expression and
the clinicopathologic features of PCa patients after RP
are summarized in Table 1. Positive protein expression
of UHRF1 was correlated with the Gleason score (Fig. 6a
and Table 1), pathological stage (Fig. 6b and Table 1),
preoperative PSA level (Fig. 6c and Table 1), and BCR
(p = 0.000), but was not significantly associated with
other clinical characteristics, such as age, LN status,
tumour margins, or capsular invasion.
Expression of human UHRF1 protein and BCR of PCa
We evaluated the ability of UHRF1 staining to predict
the risk of BCR in patients with PCa who had undergone
RP. In PCa specimens, UHRF1 expression was higher in
patients who experienced BCR compared to patients
who did not (p = 0.000; Table 1). To determine whether
UHRF1 expression was clinically significant, we assessed
the BCR risk in patients who were UHRF1-positive or
UHRF1-negative using the Kaplan-Meier method (Fig. 7).
The mean BCR-free time and 5-year BCR-free survival
rates for the UHRF1-negative and UHRF1-positive PCa
patients after RP are shown in Table 2. Comparing
UHRF1-negative to UHRF1-positive patients, the 5-year
BCR-free survival rates were higher (51.8 vs. 12.4 %,
p < 0.000) and the mean BCR-free time was longer
(38.95 vs. 23.00 months, p < 0.000) in UHRF1-negative
patients. These results indicate that UHRF1 positivity
was correlated with a shorter BCR-free survival time.
Finally, we employed a Cox proportional hazards model
to assess the independent predictors for BCR-free survival
(Table 3). Expression of the UHRF1 protein was an inde-
pendent prognostic factor of PCa patient outcome after
RP. Thus, UHRF1 protein expression level could predict
the risk of the BCR after RP.
Discussion
UHRF1 is an oncogenic factor that is overexpressed in
numerous cancers [25–27]. UHRF1 is able to read both
DNA methylation and histone methylation, physically
linking these two epigenetic markers, because UHRF1
possesses several domains (e.g., ubiquitin-like domain,
PHD finger, SRA domain, and ring finger) [28]. The
Fig. 5 UHRF1 enhanced cell migration. Cells (2 × 104) were transfected with siUHRF1-535, siUHRF1-1453, or scrambled siRNA control and seeded
into the upper chamber of a Transwell plate in 0.1 mL media (supplemented with 1 % FBS). At 120 h, cells that had migrated through
to the bottom of the Transwell were stained and counted under a reverse microscope. Knockdown of UHRF1 inhibited cell migration in
PC-3 cells (a and b). Each experiment was performed in triplicate (n = 3). Bars represent mean ± SD
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frequent hypermethylation of promoters of tumour sup-
pressor genes and the overexpression of enzymes that
catalyse histone modifications are the two main hall-
marks of epigenetic processes in cancer genesis [29, 30].
UHRF1 has been shown to act effectively as a marker to
distinguish pancreatic adenocarcinoma, chronic pancrea-
titis, and normal pancreas tissue [18]. Overexpression of
UHRF1 has also been described in breast cancer cells,
Fig. 6 UHRF1 expression in PCa tissue samples and associations with PCa clinical variables. Positive protein expression of UHRF1 was correlated
with the Gleason score (a), pathological stage (b), preoperative PSA level (c). d UHRF1 staining was negative in normal prostate tissues.
e Representative positive staining of UHRF1 was mainly detected in epithelia cells on tissue arrays. f Representative example of a tumour
sample, on which positive staining could be found both in the epithelial cells and stromal tissue. Statistical comparisons between groups
of normalized data were performed using Mann–Whitney U-test according to the test condition. Significance was defined as p < 0.05
(*, p < 0.05; **, p < 0.01; ***, p < 0.001)
Wan et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:34 Page 10 of 14
and could be linked to the degree of breast cancer ag-
gression and its pathological stage [31]. These clinical
studies show that incorporating assays for UHRF1 ex-
pression could improve the specificity and sensitivity of
current cancer diagnostic tests.
In this study, we found that UHRF1 is overex-
pressed in PCa cells and tissue samples. To explore
the potential contribution of UHRF1 to PCa develop-
ment, we knocked down UHRF1 using siRNA in two
PCa cell lines. The siRNAs effectively knocked down
UHRF1 expression in PCa cells. UHRF1 knockdown
significantly reduced the proliferation and growth of
LNCaP and PC-3 cells by repressing cell cycle pro-
gression and cell migration (PC-3 cells), but increased
the percentage of cells undergoing apoptosis. More-
over, we also found overexpression of UHRF1 signifi-
cantly promoted cell proliferation and inhibited cell
apoptosis of LNCaP. The parts of the results in our
study are consistent with Babbio’s findings [24]. Sev-
eral studies have explored the potential roles of
UHRF1 in cancer development. Jenkins et al. reported
that siRNA-mediated knockdown of UHRF1 signifi-
cantly inhibited the growth of A549, HeLa, and
H1299 cells [32]. Daskalos et al. observed reduced
cell proliferation and migration properties in lung
cancer cells after knocking down UHRF1 [33]. To-
gether with our findings, these observations suggest
that increased UHRF1 expression may be involved in
PCa carcinogenesis.
The clinical significance of the observed overexpres-
sion of UHRF1 in PCa has not been well characterized.
We found that overexpression of UHRF1 was signifi-
cantly correlated with the Gleason score, pathological
stage, preoperative PSA level, and BCR, but not with
age, LN status, tumour margins, or capsular invasion.
Our results indicated a strong correlation between
Table 1 Correlation between UHRF1 protein expression and clinicopathologic features in PCa patients after RP
Features UHRF1 protein expression P-Value
Negative Positive
aAge at Surgery (n = 225)
Median (Range) 68.00 (65.55-67.81) 67.00 (65.28-67.78) 0.832
Mean 66.68 66.50
bPathological Stage (pT) (n= 225)* 0.028
pT2-pT3a 97 73
pT3b 22 33
cLymph Node Status (n= 225) 0.143
Positive 7 12
Negative 112 94
cTumor Margins (n= 225) 0.825
Positive 20 19
Negative 99 87
cCapsular Invasion (n= 225) 0.116
No Invasion 114 96
Invasion 5 10
dPre-operation PSA Level (ng/ml) (n= 225) **
Median (Range) 18.00 (21.69, 30.42) 26.47 (31.30, 42.63) 0.002
Mean 26.06 36.97
bGleason Score (n = 225)*
Gleason≤6 42 22 0.016
Gleason≥7 77 84
bBiochemical Recurrence (n = 225)**
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UHRF1 expression and the BCR-free survival of patients.
Kaplan-Meier analysis showed that PCa patients with
positive UHRF1 expression had a high probability of ex-
periencing BCR after RP compared to UHRF1-negative
patients. Cox regression analysis suggested that UHRF1
expression could be a prognostic factor for predicting
the risk of BCR.
Despite the combination of increasingly refined sur-
gical techniques and a reduced incidence of surgical
complications, the variable disease course in PCa
eventually leads to recurrence in about one-third of
patients after RP [34]. Distant or local recurrence of
PCa does not occur without BCR [35]. Therefore, to
achieve the best possibility of long-term disease-free
survival for PCa patients after RP, the BCR risk of
PCa patients should be assessed. Recent studies have
tried to determine tumour cell biological characteris-
tics that are potential prognostic factors. Identification
of such factors might help in determining the optimal
treatment strategy based on the biology of the indi-
vidual tumour [36]. Based on our findings, we suggest
that PCa patients with low UHRF1 expression should
undergo regular monitoring of serum PSA and clin-
ical symptoms. In contrast, PCa patients with high
UHRF1 levels could benefit from more extensive
monitoring, such as ultrasound-guided biopsy, com-
puted tomography, magnetic resonance imaging, and
bone scans.
Conclusions
In conclusion, UHRF1 expression was upregulated in
PCa cell lines and samples. Moreover, UHRF1 knock-
down decreased cell proliferation and growth by
repressing cell cycle progression and migration, but
enhanced apoptosis of PCa cells. Given these results,
UHRF1 may be a potential biomarker that can be
used as a therapeutic target for PCa. UHRF1 expres-
sion in PCa was associated with poorer patient prog-
nosis; therefore, UHRF1 may be a useful prognostic
factor for predicting the risk of BCR in PCa patients
after RP.
Fig. 7 Biochemical recurrence (BCR)-free survival of UHRF1-negative and UHRF1-positive PCa patients. The Kaplan-Meier method was used to
draw survival curves for each group of patients based on UHRF1 expression
Table 2 5-year BCR-free survival rates and median BCR-free time
for negative and positive UHRF1 protein expression groups of








Mean (months) 95 % CI
Negative 119 51.8 % 38.95 34.2-43.7
Positive 106 12.4 % 23.00 19.1-26.9
P<0.001
Table 3 Multivariate analysis of BCR-free survival for all PCa
patients after RP
Comparison P-Value Hazard ratio for recurrence 95 % CI
Pre-operation PSA 0.003 1.008 1.003, 1.014
Tumor margins 0.005 0.434 0.242, 0.781
UHRF1 expression 0.005 1.754 1.184, 2.597
Gleason score 0.001 2.366 1.438, 3.892
Pathological Stage 0.035 1.544 1.031, 1.014
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